Mpox Vaccine: Emergent BioSolutions' Smallpox Vaccine Gets FDA Nod For Expanded Use For Individuals At High Risk Of Mpox Infection
Portfolio Pulse from Vandana Singh
The FDA has approved Emergent BioSolutions' ACAM2000 vaccine for expanded use to prevent mpox in high-risk individuals. This approval is based on human safety data and animal studies. Emergent will donate 50,000 doses to Central Africa, and the vaccine is stockpiled in the U.S. and internationally. EBS stock rose 15.70% following the news.
August 30, 2024 | 11:43 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Emergent BioSolutions received FDA approval for its ACAM2000 vaccine to prevent mpox in high-risk individuals. This regulatory milestone led to a 15.70% increase in EBS stock price.
The FDA approval of the ACAM2000 vaccine for mpox prevention is a significant regulatory achievement for Emergent BioSolutions, likely increasing investor confidence and demand for EBS stock, as evidenced by the 15.70% premarket price increase.
CONFIDENCE 100
IMPORTANCE 90
RELEVANCE 100